Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Ipsen - Disrupting the landscape: the Plus One in RCC and NSCLC

Expanding the armamentarium with IO-TKIs combinations – what can be learnt from RCC for the future of NSCLC?

Date

11 Sep 2022

Session

Ipsen - Disrupting the landscape: the Plus One in RCC and NSCLC

Topics

Tumour Site

Renal Cell Cancer;  Non-Small Cell Lung Cancer

Presenters

Guillermo Antonio De Velasco Oria

Authors

L. Albiges1, L. Paz-Ares2, S.K. Pal3, J. Bedke4, G.A. De Velasco Oria5

Author affiliations

  • 1 Medical Oncology Department, Institut Gustave Roussy, 94805 - Villejuif, Cedex/FR
  • 2 Medical Oncology Department - Edificio Maternidad 2ª Planta, Hospital Universitario 12 de Octubre, 28041 - Madrid/ES
  • 3 City of Hope Comprehensive Cancer Center, 91010 - Duarte/US
  • 4 Urology Dept., Crona Kliniken - Universitätsklinikum Tübingen, 72076 - Tübingen/DE
  • 5 Medical Oncology Department, Hospital Universitario 12 de Octubre, 28041 - Madrid/ES
More

Resources

Login to access the resources on OncologyPRO.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.